Phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity and efficacy of potential SARS-COV-2 RNA vaccines against COVID-19 in healthy people

  • Statistics projects, data management and information systems

Period: 2020 – 2022

Researchers: 

  • Dr. Mabel Berrueta
  • Lic. Álvaro Ciganda
  • Lic. Rocío Rodriguez
  • Candela Stella

Objective: PHASE 3, evaluate the effectiveness of the BNT162 vaccine against COVID-19 in participants without previous infection.

Type of study: Clinical trial

Financing: ITRIALS